Coronary disease & ACSSecondary analysis

Impact of Diabetes on Outcomes of Contemporary Percutaneous Coronary Intervention (PCI) Guided by Optical Coherence Tomography (OCT) vs Angiography

JACC Cardiovasc IntervPublished

  • Secondary analysis of the ILUMIEN IV randomised trial

Authors' conclusion

In the large-scale ILUMIEN IV trial, patients with diabetes remained at increased risk for adverse events after PCI compared with nondiabetic patients despite the use of OCT procedural guidance. Patients with diabetes and complex lesions were at particularly high risk for adverse outcomes after PCI.

Study context

Population
Patients randomised to OCT-guided vs angiography-guided PCI in ILUMIEN IV
Participants
1,044 vs 1,443
Comparison
Diabetes vs no diabetes
  • Diabetesn = 1,044
  • No diabetesn = 1,443reference
Primary endpoint
TVF and serious MACE
Follow-up
2 years

Primary result

TVF

Adjusted hazard ratio

1.48

95% CI 1.09–2.02

P = 0.01

By group

Diabetes vs No diabetes
adjusted HR 1.48 (95% CI 1.09–2.02); P = 0.01

As reported in the abstract

Further findings

OutcomeDiabetesNo diabetesadjusted HR (95% CI)P value
Serious MACE · 2 years5.3%2.7%1.77 (1.14–2.76)P = 0.01

OCT vs angiography guidance: Target vessel failure (TVF) and serious major adverse cardiovascular events (MACE)

OCT guidance did not reduce TVF or serious MACE; consistent with and without diabetes
  • Pinteraction = 0.41 and 0.20, respectively

Original publication

Impact of Diabetes on Outcomes of Contemporary PCI Guided by OCT vs Angiography. JACC Cardiovasc Interv. Published 14 September 2026. doi:10.1016/j.jcin.2026.06.028

Summarised from the published abstract; every number is checked against it